Essex Woodlands has promoted five: Scott Barry and David Yang were promoted to managing director in Shanghai; Toby Sykes was promoted to partner and Evis Hursever to principal in the firm’s London office; and Tamara Elias was promoted to partner in New York.
Essex Woodlands, a leading healthcare growth equity firm with a global investment practice, has announced, effective January 1, 2013, the promotion of five key investment professionals in their Shanghai, London and New York offices. Scott Barry and David Yang were promoted to Managing Director in Shanghai, Toby Sykes to Partner and Evis Hursever to Principal in London, and Tamara Elias to Partner in New York. The promotions were announced in recognition of these professionals’ roles in identifying successful growth equity investments, working closely with portfolio companies’ management teams to accelerate revenue and profit growth, and creating substantial value to all shareholders through attractive exits by trade sales.
Martin P. Sutter, a co-founder and Managing Director, said: “I am extremely proud of what these talented professionals have accomplished. They have made substantial contributions towards building our growth equity investment practice and have demonstrated their ability to make money for our investors. They have all proven their ability to take on increasing leadership roles within the firm.”
Petri Vainio, M.D., Ph.D., a Managing Director who heads the London office and supervises the Essex Woodlands international investment practice, commented: “These individuals will continue to play a key role in the growth of Essex Woodlands’ international investment practice. With the recent opening of our Shanghai office, we look forward to making more growth equity investments in rapidly growing healthcare companies in Europe, China, as well as in Latin America.”
Steve Wiggins, a Managing Director who heads the New York office, added: “Scott Barry and Tamara Elias have been instrumental in building our New York office. While Scott will move to co-head our Shanghai office, Tamara will continue to work closely with me to add to our growing portfolio of investments in healthcare service and information technology companies that take advantage of the rapid changes in the US healthcare system.”
Scott Barry and David Yang promoted to Managing Directors in the Shanghai office
Scott Barry has been promoted to Managing Director and co-head of the Essex Woodlands office in Shanghai, China. Mr. Barry has also been elected to become a member of the investment committee of Essex Woodlands. With over 15 years of experience in the healthcare industry and investment banking, Mr. Barry has been a Partner in the Essex Woodlands New York office since 2006, covering specialty pharmaceuticals, biotechnology, medical device, and healthcare service sectors. Mr. Barry has led several major transactions in Essex Woodlands’ growth equity practice, including the recent spin-out of Bioventus from Smith & Nephew. He also serves on the Boards of current growth equity investments United Orthopedics and Velcera, and previously served on the Boards of Orthovita, Inc. (acquired by Stryker) and Victory Pharma (acquired by Shionogi). Mr. Barry is the previous Global Head of Pharma M&A and Collaborations at Novartis Pharma AG where he was responsible for global acquisitions, equity investments and corporate partnerships across all therapeutic areas.
David Yang has been appointed Managing Director and co-head of the Essex Woodlands office in Shanghai together with Scott Barry. Mr. Yang joined Essex Woodlands in April 2012 and has over 10 years of experience in healthcare private equity, management consulting and investment management in China and the US. Fluent in Chinese and English, Mr. Yang was previously an Executive Director with Warburg Pincus’ China healthcare team. Mr. Yang was involved with Warburg Pincus’ successful investments in China’s leading privately-owned pharmaceutical distributor CITIC Pharmaceuticals (acquired by Shanghai Pharma) and in China’s leading cardiovascular medical device company Lepu Medical (SZSE: 300003). Mr. Yang was also closely involved in Warburg Pincus’ investments in China’s leading orthopedics implant manufacturer Walkman Biomedical and in state-owned branded generic pharmaceutical and nutritious products giant Harbin Pharmaceuticals. Previously, Mr. Yang served on McKinsey & Company’s corporate finance team, Fidelity Investment’s healthcare investment team and Morgan Stanley’s investment banking team.
Toby Sykes promoted to Partner and Evis Hursever promoted to Principal in the London office
Toby Sykes, Ph.D., who joined the London office of Essex Woodlands in 2007 as Principal, has been promoted to Partner. Dr. Sykes has played a key role in supporting several of Essex Woodlands’ international growth equity investments, including Healthcare Brands International (acquired by Meda AB) and EUSA Pharma (acquired by Jazz Pharmaceuticals). Most recently, Dr. Sykes has managed Essex Woodlands’ investment in the growth buy-out of Biotoscana, a leading Latin American specialty pharmaceutical company. Dr. Sykes also serves on the board of Chroma Therapeutics and works closely with Essex Woodlands’ investment team in Molecular Partners. Prior to joining Essex Woodlands, Dr. Sykes was Director of Business Development at Cephalon, and previously held positions in the corporate finance practices of Deloitte & Touche and Arthur Andersen in London, where he worked on several European transactions in the healthcare, life sciences and private equity sectors.
Evis Hursever, Ph.D., who joined the London office of Essex Woodlands in 2011 as Vice President, has been promoted to Principal. Dr. Hursever has played an instrumental role in assessing attractive international growth equity investment opportunities and has contributed to Essex Woodlands’ investments in Biotoscana and Molecular Partners. Prior to joining Essex Woodlands, Dr. Hursever was a senior manager in the European life sciences and healthcare team at LEK Consulting where she was involved in several numerous large healthcare transactions and assignments for LEK’s pharmaceutical industry and private equity clients. Previously , Dr. Hursever worked in the Merrill Lynch healthcare investment banking team in London, providing M&A advisory services to a broad range of life sciences and healthcare companies.
Tamara Elias promoted to Partner in the New York office
Tamara Elias, M.D., who joined the New York office of Essex Woodlands in 2007 as Principal, has been promoted to Partner. Dr. Elias has played a key role in Essex Woodlands’ growth equity investments in healthcare services and information technology companies BreatheAmerica, an operator of outpatient clinics focused on the diagnosis and treatment of chronic airway diseases; MEDSEEK, a provider of web-based tools to connect hospitals and healthcare organizations with physicians and patients; and Millennium Pharmacy Systems, a provider of pharmacy services to the long-term care organizations. Dr. Elias also worked closely with Essex Woodlands growth equity investment in ATS Medical (acquired by Medtronic). Dr. Elias has over 15 years of experience in healthcare, and joined Essex Woodlands after six years as a senior engagement manager at McKinsey & Company, where she advised healthcare companies in strategic, operational and business development. Dr. Elias is a Kauffman Fellow and an organizing member of the MedtechWomen conference for women leaders in the medtech industry.